RxDoctor Payments Data

Mei Ngai

Family · Los Angeles, CANPI 1417472531

Payments from drug & device makers

$4,106in general payments, 2019–2025

Across 192 payments — averaging $21.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$987
  • AstraZeneca$750
  • Gilead$677
  • Amgen$516
  • Bayer$343
  • Amarin Pharma, Inc.$205
  • plus $628 from 11 others

What the payments were for

  • Consulting fees$1754%
  • Food & beverage$3,93196%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,106 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl479$271,493
FarxigaDapagliflozin Propanediol165$188,209
JardianceEmpagliflozin143$170,533
ProliaDenosumab91$153,773
Diclofenac Epolamine227$136,181
JanuviaSitagliptin Phosphate129$132,565
VemlidyTenofovir Alafenamide82$127,448
JanumetSitagliptin Phos/Metformin Hcl95$91,391
TradjentaLinagliptin101$81,759
Diclofenac Sodium163$77,269
CreonLipase/Protease/Amylase56$72,913
Icosapent Ethyl236$72,079
JentaduetoLinagliptin/Metformin Hcl81$65,951
RestasisCyclosporine78$57,579
EliquisApixaban54$54,038

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Jentadueto, Glyxambi$112$354,266356 claims
AstraZenecaFarxiga, Brilinta$750$193,131180 claims
AbbVieCreon, Restasis, Linzess$987$175,682214 claims
AmgenProlia$516$153,77391 claims
GileadVemlidy$677$127,44882 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$68$37,28475 claims
IBSA Pharma Inc.Licart$22$26,04135 claims
Johnson & JohnsonXarelto$57$21,14519 claims
BayerKerendia$343$20,94320 claims
Scilex Pharmaceuticals Inc.Ztlido$18$9,18414 claims
Smith+NephewSantyl$35$8,30016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →